TAT-1033PELP1

TAT-1033PELP1 is a novel cell-permeable peptide inhibitor designed to block the ATM-PELP1-p53 signaling axis. Developed by researchers at the University of Texas Health Science Center at San Antonio, the peptide is based on the unique sequence surrounding the serine 1033 (S1033) phosphorylation site of proline, glutamic acid, and leucine-rich protein 1 (PELP1), a proto-oncogene overexpressed in breast cancer. By mimicking this sequence, TAT-1033PELP1 acts as a competitive inhibitor that significantly reduces ATM-mediated phosphorylation of endogenous PELP1. In triple-negative breast cancer (TNBC) cells harboring mutant p53, treatment with TAT-1033PELP1 disrupts the functional interaction between PELP1 and mutant p53, leading to a significant loss of cell viability and increased apoptosis in response to genotoxic stress, as well as reduced migratory potential.

Other names

TAT-1033 inhibitor peptideTAT1033 inhibitor peptideTAT 1033 inhibitor peptideTAT-1033PELP1 inhibitorTAT1033PELP1 inhibitorTAT 1033PELP1 inhibitorTAT-1033PELP1 peptideTAT1033PELP1 peptideTAT 1033PELP1 peptideTAT-PELP1 inhibitorTAT-PELP-1 inhibitorTAT-PELP 1 inhibitor